Skip to search
Skip to main content
Back to Search
Start Over
Phase I trial: PI3K alpha inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
Authors :
Shah, P. D. Moynahan, M. E. Modi, S. Caravella, B. A. Datko, F. M. Zamora, S. Comen, E. Gilewski, T. Sugarman, S. M. D Andrea, G. Lake, D. E. Goldfarb, S. B. Patil, S. Covey, A. Berger, M. F. Lacouture, M. E. Larry Norton Hudis, C. A. Baselga, J. Chandarlapaty, S. Dickler, M. N.
Source :
Memorial Sloan Kettering Cancer Center
Details
Database :
OpenAIRE
Journal :
Memorial Sloan Kettering Cancer Center
Accession number :
edsair.dedup.wf.001..14ffee999c22736e4e24c336b65495b3